Circuit-level mechanisms of cerebral compensation in Parkinson's disease

Circuit-level mechanisms of cerebral compensation in Parkinson's disease - Cerebral compensation in Parkinson's disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON40985

Enrollment

Registered

2014-08-28

Start date

2014-11-04

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

eye movements Parkinson's disease

Interventions

All participants will receive single-pulse transcranial magnetic stimulation (TMS), and continuous theta-burst transcranial magnetic stimulation (cTBS).

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: A person with Parkinson's disease must meet the following: - Idiopathic Parkinson*s disease according to UK brain bank criteria. - Mild to moderate disease severity (Hoehn and Yahr 1-3). - Dopaminergic therapy with a clear clinical response of non-tremor symptoms (bradykinesia, rigidity). - Right-handed - Normal/corrected-to-normal vision;A control subject must meet the following: - right handed - normal / corrected to normal vision - and be considered healthy

Exclusion criteria

Exclusion criteria: - Epilepsy, convulsion or seizure (TMS) - Serious head trauma or brain surgery - Large or ferromagnetic metal parts in the head (except for a dental wire) - Implanted cardiac pacemaker or neurostimulator - Pregnancy - Familial epilepsy - Any other exclusion as per TMS screening form - Neurological or psychiatric co-morbidity (e.g. stroke, depression). - Severe head tremor or dyskinesias - cognitive impairment (MMSE

Design outcomes

Primary

Measure	Time frame
The main behavioural parameters will be the differences in eye movement behaviours depending on cTBS condition (Arm 1) and cTBS and TMS single-pulse timing (early versus late with respect to an eye-movement) (Arm 2). The main neurobiological parameters will be differences in fMRI activation patterns in oculomotor regions depending on cTBS location (Arm 1), and changes in cerebral blood flow after cTBS (Arm 2).	—

Measure

Time frame

The main behavioural parameters will be the differences in eye movement behaviours depending on cTBS condition (Arm 1) and cTBS and TMS single-pulse timing (early versus late with respect to an eye-movement) (Arm 2). The main neurobiological parameters will be differences in fMRI activation patterns in oculomotor regions depending on cTBS location (Arm 1), and changes in cerebral blood flow after cTBS (Arm 2).

—

Secondary

Measure	Time frame
In Arm 1, the secondary study parameters will be differences in fMRI activation patterns in a larger oculomotor circuit. Additionally, we will assess any changes in tremor-related activity following cTBS. In Arm 2, we will more precisely examine the TMS pulse timings on eye-movement behavior.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)